Concurrent in vitro release of silver sulfadiazine and bupivacaine from semi-interpenetrating networks for wound management.
In situ photopolymerized semi-interpenetrating networks (sIPNs) composed of poly(ethylene glycol) and gelatin are promising multifunctional matrices for a regenerative medicine approach to dermal wound treatment. In addition to previously demonstrated efficacy in critical defects, sIPNs also function as drug delivery matrices for compounds loaded as either soluble or covalently linked components. Simultaneous release of silver sulfadiazine and bupivacaine from the sIPN would provide multiple-hit management of dermal wounds that minimizes infection, and manages pain along with sIPN absorption of exudates and facilitation of epidermal regrowth. We characterized the release of soluble silver sulfadiazine and bupivacaine and compared it with an established release model. Efficacy of released silver sulfadiazine was confirmed in vitro on Staphylococcus aureus, methicillin resistant S. aureus, and Pseudomonas aeruginosa. Bupivacaine loaded without silver sulfadiazine showed incomplete release, whereas simultaneous loading with silver sulfadiazine facilitated 100% bupivacaine release. Silver sulfadiazine released at 98% without bupivacaine and 96% with bupivacaine. Silver sulfadiazine released onto bacterial cultures inhibited all three strains dose dependently. sIPNs effectively release bupivacaine and silver sulfadiazine while maintaining the antimicrobial activity of silver sulfadiazine. Drug loaded sIPNs have potential to improve wound management by providing multi-drug delivery along with an effective wound treatment.
Kleinbeck
Kyle R
KR
School of Pharmacy, College of Engineering, University of Wisconsin-Madison, Wisconsin 53705, USA.
Bader
Rebecca A
RA
Kao
Weiyuan John
WJ
D000779:Anesthetics, Local / Q000008:administration & dosage*; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage*; D002045:Bupivacaine / Q000008:administration & dosage*; D002056:Burns / Q000188:drug therapy / Q000382:microbiology; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D066298:In Vitro Techniques; D016106:Methicillin Resistance / Q000187:drug effects; D009779:Occlusive Dressings; D011108:Polymers; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012837:Silver Sulfadiazine / Q000008:administration & dosage*; D013211:Staphylococcus aureus / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects*
D000779:Anesthetics, Local; D000891:Anti-Infective Agents, Local; D004337:Drug Carriers; D011108:Polymers; D012837:Silver Sulfadiazine; D002045:Bupivacaine